Funding Opportunities

Filter by area:

Fixed Deadline Funding

Powered by Barclays Eagle Labs, the P4 programme curates a unique ecosystem to support precision medicine SMEs develop research into world leading technology, gain regulatory approval as well as adoption into the UK and international healthcare systems.

Applications for the 2021 Accelerator programme are officially open.

Opening for its third cohort, the P4 scaling programme seeks to support the world’s leading precision medicine startups. We want every company within precision medicine to apply. To gain the full benefit from this programme, we recommend that companies:

Work in the area of Precision Medicine*
Be early to mid-stage medical device, diagnostic or digital health companies
Have not yet closed a Series B
Be data-driven
Be able to demonstrate their route to market within a timeframe of 12 to 18 months
Have already received seed/grant funding
Show team credibility (at least 3 members with complimentary and relevant expertise)
Have Data Scientist involvement
Use AI

*Precision (aka personalised) medicine is an approach that will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people.

Programme

The P4 programme is led by Professor Phil Beales, Chair of the UCL Institute of Precision Medicine, Professor of Medical and Molecular Genetics at the UCL Great Ormond Street Institute of Child Health and UCL Partners. It is further supported by Capital Enterprise, London’s startup experts. Cross-faculty support led by the UCL Institute for Precision Medicine, leverages the talent pool of academics at UCL and its partners. Capital Enterprise has experience of supporting and scaling tech SMEs as well as providing access to unique funding streams to ensure SMEs thrive.

The delivery of precision medicine requires the academia, healthcare and industry sectors to work together. Accordingly, we offer a 6 to 12 month scale up programme connecting your company with all these different sectors to create a clear innovation pathway. Together with our strategic partners, participants benefit from dedicated workshops, one-to-one expert advice, industry and academic tech expertise, regulatory pathway support, testbeds and trial opportunities, specialised investor introductions and access to key decision makers.

At the end of the programme each company will have the chance to present to industry and investors to increase traction and pique investors interest for the next round of investment. Once the programme ends, as P4 alumni, companies will be able to carry on with participation in clinical trials and R&D with our partners, as well as access industry events, focused networking events, and other scale-up opportunities.

‍

Organisations can apply for a share of £120,000 inclusive of VAT, to develop an AI tool to provide accessible heart failure data from routine patient information.

Competition opens: Monday 12 October 2020
Competition closes: Wednesday 9 December 2020 11:00am

This is a Small Business Research Initiative (SBRI) competition funded by NHS Scotland. Successful applicants will receive 100% funding and have access to advice from NHS Tayside, NHS Greater Glasgow and Clyde Health Board and the University of Dundee Health Informatics Centre.

The aim of this competition is to develop a system that can provide accessible, timely and accurate data on heart failure from healthcare information which is routinely collected in primary and secondary care.

We are looking for digital and data-driven partners to work with clinical and informatics experts in Tayside.

Together they will develop a solution to automatically evaluate and accurately extract meaningful data from a number of healthcare data sources, such as:

image
quantitative
unformatted text

The output will be a national dashboard to give clinicians, managers and policymakers timely access to data so that they can manage, develop or improve patient care.

This is phase 1 of a potential 2-phase competition. A decision to proceed with phase 2 will depend on the outcomes from phase 1 and assessment of a separate application into a subsequent phase 2 competition.

Only successful applicants from phase 1 will be able to apply to take part in phase 2.

Phase 1: research and development contracts, feasibility study

The first phase involves research and development (R&D) contracts being awarded to demonstrate technical feasibility of the proposed solution. A total of up to £40,000 inclusive of VAT, is allocated to this phase.

Feasibility study R&D contracts will be up to £10,000 inclusive of VAT. This is for each project for up to 3 months.

We expect to fund up to 4 projects. The assessors will consider fair value in making their evaluation.

We would welcome bids from a single entity that bring together sector specialists

Phase 2: research and development contracts, prototype development and testing

The second phase will involve up to 2 R&D contracts being awarded to businesses chosen from the successful phase 1 applicants. Up to £40,000 inclusive of VAT, will be allocated for each contract, in order to develop a prototype and undertake field testing for up to 15 months.

The contract is completed at the end of phase 2, and the successful business is expected to pursue commercialisation of their solution.

Any adoption and implementation of a solution from this competition would be the subject of a separate, possibly competitive, procurement exercise. This competition does not cover the purchase of any solution.

In applying to this competition you are entering into a competitive process. This competition closes at 11am UK time on the date of the deadline.

‍

Latest News

Secure Your Data

Latest Events

Funding Opportunities

Fixed Deadline Funding

Open Funding